Crucial Information for Owners of Cats with FIP

✅ Effective treatment for FIP has existed since 2019.
The antivirals GS-441524 and remdesivir have demonstrated cure rates of over 90% in thousands of cases treated worldwide. The prognosis for FIP has changed radically.

If your cat has been diagnosed with FIP, do not waste time. Early antiviral treatment is essential for therapeutic success. Every day counts.

Find Out More About FIP →

TL;DR – The Essentials of FIP Treatment

  • Before 2017: No effective cure existed; treatments were palliative only
  • 2019 breakthrough: Dr Niels Pedersen publishes evidence on GS-441524
  • Key antivirals: GS-441524, remdesivir (Veklury®), GC-376, molnupiravir
  • Success rate: >90% cure rate with appropriate antiviral protocols
  • Duration: Standard 84-day protocols; neurological cases may require longer
  • Availability: Legal in multiple countries via compounding pharmacy

Table of Contents

1. Historical Context: Before Antivirals

FIP as an Incurable Disease

📖 Historical Perspective

Before 2017, Feline Infectious Peritonitis was considered a death sentence for affected cats. The available treatments were purely palliative, aimed at reducing clinical signs and temporarily improving quality of life.

Cats diagnosed with FIP generally died or were euthanised within a few weeks of diagnosis, with a devastating prognosis that left owners and vets without effective options.

Traditional Therapeutic Approaches

🔬 Three Main Strategies Pre-2017

FIP treatment encompassed different approaches throughout its history:

  • Non-specific antiviral approach: Use of drugs similar to those employed in other viral infections, with the aim of inhibiting viral replication
  • Anti-inflammatory approach: Aimed at suppressing the inflammatory response, frequently combined with interferon
  • Immunostimulant approach: Aimed at non-specifically stimulating the immune system (such as Polyprenyl Immunostimulant – PPI)

Limitations of Traditional Treatments

⚠️ Clinical Reality Before Antivirals

Until relatively recently, the range of drugs available for FIP treatment was extremely limited and exclusively palliative in nature. Available options included:

  • Temporary symptom relief with no real impact on disease progression
  • Significant side effects from immunosuppressants
  • Absence of solid scientific evidence on long-term benefits
  • Invariably fatal prognosis within weeks or months

2. Traditional Treatments (pre-2017)

Historical Therapeutic Options

💊 Traditional Palliative Drugs

The options available before the era of specific antivirals included multiple drug categories, none of which offered a genuine cure:

Category Drugs Aim
Corticosteroids Prednisolone, Methylprednisolone, Dexamethasone Anti-inflammatory and immunosuppressant
Alkylating agents Cyclophosphamide Immunosuppressant
Cytokine inhibitors Pentoxifylline Anti-vasculitis
Antibiotics Doxycycline Antiviral effect in vitro
Immunosuppressants Ciclosporin A Anti-coronavirus activity
Immunostimulants Feline omega interferon (rfIFN-ω), PPI Immunological stimulation
Other Itraconazole, Stem cells Experimental

Corticosteroids and Alkylating Agents

💊 Prednisolone and Cyclophosphamide

Steroids and alkylating agents have both anti-inflammatory and immunosuppressant effects. They were used to reduce clinical signs in affected cats.

  • Outcome: No evidence of positive effects on disease progression
  • Benefit: Temporary symptom relief in some patients
  • Use: Monotherapy or in combination
  • Limitation: No impact on long-term survival

Pentoxifylline

🔬 Cytokine Inhibitor

Pentoxifylline, a specific cytokine inhibitor, was used extensively in FIP treatment due to its effect on vasculitis in human medicine.

Rationale: Vasculitis is one of the main components of FIP pathophysiology, so it was theorised that reducing this process could improve prognosis.

Ciclosporin A

🦠 Anti-Coronavirus Activity

Ciclosporin A has been shown to possess anti-coronavirus activity through an interesting mechanism:

  • Interaction with immunophilins and the coronavirus non-structural protein Nsp1
  • Blockade of replication of coronaviruses of any genus
  • Efficacy against human, feline and avian species
  • Cyclophilin inhibitors such as ciclosporin A blocked viral replication

Recombinant Feline Omega Interferon

💉 rfIFN-ω

Recombinant feline interferon is authorised for use in cats. For FIP, it was used:

  • Alone as monotherapy
  • In combination with glucocorticoids

Its efficacy was limited and did not significantly alter the fatal prognosis of the disease.

Other Experimental Alternatives

🔬 Additional Therapeutic Attempts

  • Doxycycline: Used anecdotally due to some inhibitory effect on viral replication in vitro
  • Polyprenyl Immunostimulant (PPI): Some authors documented successful cases in non-effusive FIP
  • Itraconazole + prednisolone: Studied combination with limited results
  • Haematopoietic stem cells: Experimental therapy without demonstrated consistent efficacy

📊 Conclusion on Traditional Treatments

These treatments have been completely superseded by more effective options.

Some of them may still be used in a complementary role as supportive measures within antiviral protocols, particularly for symptom management in the early phases of treatment.

3. The Antiviral Revolution

Dr Niels Pedersen: Pioneer in FIP Treatment

🏆 Groundbreaking Research

The work of Dr Niels Pedersen, a leading veterinarian and professor emeritus at the University of California, Davis, has been fundamental to understanding and combating Feline Infectious Peritonitis.

Notable career milestones:

  • Since the 1970s: Dedicated his career to the study of feline infectious diseases
  • 2008: Wrote a comprehensive review of all FIP research to date
  • 2017: Initiated studies with GC-376 showing promising results
  • 2019: Published definitive evidence on GS-441524, permanently changing the prognosis of FIP

Discovery of Specific Antivirals

🔬 A Paradigm Shift in 2017–2019

Dr Pedersen's research culminated in the discovery of the efficacy of human antiviral drugs for treating FIP infection:

  • GC-376: Viral protease inhibitor
  • GS-441524: Nucleoside analogue with remarkable results

His 2019 publications opened a new door to hope. Today, these antivirals have demonstrated their efficacy and safety through thousands of cases treated worldwide.

Global Impact of the Discovery

🌍 Transformation of the FIP Prognosis

Following Dr Pedersen's publications, numerous scientific articles and papers have emerged confirming the effectiveness of these treatments:

  • 2019–2025: More than 50 studies published on antiviral treatment of FIP
  • Thousands of cases: Documented worldwide with success rates >90%
  • Progressive legalisation: More than 25 countries have established legal access pathways
  • Standardised protocols: Based on accumulated scientific evidence

4. GC-376: Protease Inhibitor

Mechanism of Action and History

🧬 How Does GC-376 Work?

GC-376 is a human antiviral drug that acts as a viral protease inhibitor of both feline coronavirus and the COVID-19 virus.

Mechanism: Blocks the catalytic activity of the viral protease, inhibiting its replication.

Development: Under development by the biopharmaceutical company Anivive Lifesciences for therapeutic use in humans and animals.

Scientific Evidence: 2018 Study

📊 Results of the First Study (Pedersen 2018)

Study design: Published in 2018 following research conducted in 2017, prior to the publications on GS-441524

  • Sample: 20 cats with FIP (effusive and non-effusive)
  • Exclusions: Neurological cases were excluded
  • Protocol: Dose of 15 mg/kg every 12 hours SC for 15 days
  • Initial results: 19/20 cats showed clinical improvement after two weeks
  • Relapses: Some cats relapsed between 1–7 weeks later
  • Extended treatment: Treated for a minimum of 12 additional weeks
  • Final outcome: 13 of the 19 cases did not respond to treatment
  • Survival: One third of cats survived long-term

Current Use and Limitations

⚠️ Current Role of GC-376

GC-376 presents significant limitations in clinical practice:

  • Difficult to obtain: Not widely available
  • Limited efficacy as monotherapy: Little curative success except in anecdotal cases
  • Current use: Superseded by the benefits of GS-441524

Combination Therapy: 2022 Study

✅ Combined Protocol: GS-441524 + GC-376

A second study published in 2022 demonstrated the efficacy of an alternative protocol using a combination of both antivirals:

  • Sample: 46 cases treated
  • Duration: Between 4 and 12 weeks depending on time to remission
  • Efficacy: 97.8% survival rate
  • Advantage: Distinct and synergistic mechanisms of action

Current recommended use: Reserved for cases of resistance to GS-441524 or for concomitant use with GS-441524 due to complementary mechanisms.

Dosing and Administration

💉 Dosing Protocol

Standard dose: 15 mg/kg every 12 hours

Route: Subcutaneous injection (SC)

Duration: 15–84 days depending on clinical response

Adverse Reactions and Side Effects

⚠️ Adverse Effects of GC-376

  • Transient stinging: At injection sites
  • Subcutaneous fibrosis: With prolonged use
  • Hair loss: At injection sites
  • Dental abnormalities: Delayed eruption of permanent teeth in kittens, with smaller size; second and third premolars most affected and retention of deciduous canines

5. GS-441524 and Remdesivir: The Gold Standard

Mechanism of Action and History

🧬 Nucleotide Analogues

GS-441524 and remdesivir are antivirals known as nucleotide analogues. Their mechanism of action is highly specific:

  • Molecular competition: They compete with adenosine triphosphate for incorporation into the new RNA strand
  • Synthesis termination: Their incorporation causes termination of viral RNA synthesis
  • Error accumulation: Leads to complete inhibition of viral replication

Relationship between the two: GS-441524 is the active form of remdesivir. Gilead Sciences holds the patent on remdesivir and collaborated with UC Davis on the studies conducted by Niels Pedersen.

Regulatory Status

📋 Legal and Commercial Situation

  • Remdesivir (Veklury®): In Spain, classified as exclusively human hospital use
  • WSAVA 2023: Included both antivirals on the list of essential medicines for dogs and cats
  • Plumb's Guide 2023: Updated to include both antivirals for FIP treatment
  • Current status: The drug of choice for FIP treatment

Scientific Evidence: Original 2019 Study

📊 Groundbreaking Publication (Pedersen 2019)

The study published in 2019 established the foundations of treatment with GS-441524:

  • Sample: 31 cats with naturally occurring FIP
  • Exclusions: Neurological and ocular cases were excluded
  • Completed study: 26 patients
  • Initial dosing: 2 mg/kg for 12 weeks
  • Relapse management: Cats that relapsed were treated at 4 mg/kg
  • Efficacy: 77% with a total of 25 surviving cats

Historical significance: This study describes the haematological and biochemical changes during treatment and establishes the foundations of disease control with GS-441524. Current recommended doses are higher and yield a greater rate of success.

Neurological Cases: 2020 Study

🧠 First Study Including Neurological FIP

In 2020, the first study including 4 neurological cases treated with GS-441524 was published:

  • Follow-up: 500 days post-treatment
  • Survival: 3 of 4 cases were still alive
  • Euthanised case: Due to multiple neurological relapses
  • Note: Doses used were very low compared with current protocols

The Unlicensed Market: The Mutian Controversy

⚠️ Development of the Unregulated Market

Context: Unfortunately, Gilead showed no interest in developing the molecule for veterinary use in FIP.

Consequence: Suppliers in China copied the diluent and drug concentration used in the first publications. An unlicensed product network was rapidly established via social media and the internet.

  • First company: Mutian®, a nutraceutical company promoting its active ingredient Xraphconn®
  • Outcome: The majority of products yielded promising results
  • 2024 study (University of Utah): Analysis of 87 "unlicensed" formulations concluded that most contained a higher concentration than stated

Legalisation: United Kingdom and Australia

✅ Legal Access Established Since 2021

It was not until August 2021 that certain companies in Australia and the United Kingdom succeeded in establishing legal use of GS-441524:

  • Legal basis: Absence of authorised medication for FIP
  • Achievement: First countries where GS and remdesivir could be legally obtained by veterinary surgeons
  • Impact: Paved the way for other countries

Additional Studies (2021–2023)

📚 Growing Scientific Evidence

2021 – Survey of over 300 cases:

Several US universities published results from a survey on the home use of unlicensed GS-441524 by owners. They concluded that the antiviral was highly effective in a home setting.

2021 – Oral formulation (Mutian/Xraphconn):

First publication demonstrating efficacy of an oral formula against FIP:

  • 18 cases treated
  • 14 remained alive 5–6 months post-treatment
  • 4 cases (severe effusive form) died in early stages
  • Severely affected cases were excluded

2022 – Viral shedding during treatment:

Study on coronavirus shedding in 18 cats treated with GS-441524:

  • 11/18 cats shed virus in the first 3 days, testing negative by day 6
  • 2 cats initially negative were transiently positive (1–4 weeks)
  • 5 cats never shed FCoV in faeces
  • Conclusion: Oral treatment effectively reduces viral load

Spanish and European Studies (2023–2025)

🇪🇸 Evidence from Spain

GTA-AVEPA 2023 (Bilbao): Vicky Vives Moya, Albert Lloret and Ignacio Amarillo presented retrospective results from 89 cats treated with GS-441524:

  • Effusive form: 47.2%
  • Dry form: 12.4%
  • Neurological form: 34.8%
  • Ocular form: 5.6%
  • Viral confirmation: 59.6% of cases

This was the first paper presented in Spain with extensive statistical data on FIP treatment.

Vives Moya 2025 study (over 500 cats): One of the largest studies published to date on FIP treatment with GS-441524, confirming the efficacy and safety of antiviral treatment in an extensive cohort of feline patients.

International Cat Care: Largest Study to Date (2023)

🌍 Retrospective Study of 307 Cats

In September 2023, the largest retrospective study to date using legal forms of GS-441524 and remdesivir was published:

Presentation Percentage
Effusive form 49%
Neurological form 14.3%
Other forms 36.7%

Protocols used:

  • Remdesivir alone: 33.9% of cases
  • Remdesivir + GS-441524: 55.7% of cases
  • GS-441524 alone: 10.4% of cases

Study Comparison: Success Rates

📊 Consolidated Results

Study Survival Rate Relapse Rate Cases Treated
Pedersen (original) 77% 30.77% 31
GTA 2023 (Spain) 77.50% 7.23% 89
International Cat Care 2023 84.40% 10.80% 307
Vives 2025 88.09% 8% 500+

Clear trend: More recent studies with optimised protocols show survival rates above 84–88%, with declining relapse rates.

Do You Need Information on Specific GS-441524 Protocols?

The second part of this article analyses the treatment schedule, adverse effects, interactions and monitoring in detail.

Coming soon in this complete guide

6. Molnupiravir: An Alternative for Resistant Cases

Mechanism of Action and History

🧬 EIDD-2801: Active Prodrug

Molnupiravir (EIDD-2801) is a prodrug that is rapidly converted in the plasma into the ribonucleoside β-D-N4-hydroxycytidine (NHC), also known as EIDD-1931.

Antiviral activity: Active against several RNA viruses:

  • Influenza virus
  • SARS-CoV-2
  • Ebola
  • Venezuelan equine encephalitis virus
  • Feline coronavirus

Molecular mechanism:

  1. NHC is distributed into cells
  2. The kinase enzyme converts it into ribonucleoside triphosphate (NHC-TP)
  3. The viral RNA polymerase incorporates it into the viral genome
  4. Result: accumulation of errors leading to inhibition of replication

Patent: Merck® under the brand name Lagevrio®. In Spain, exclusively for human hospital use.

Scientific Evidence

📊 Published Studies

Context: Currently, few studies are available and more research is needed on its use in feline patients. Dr Pedersen mentions it in his open communications.

Key publications on molnupiravir for FIP:

2022 Survey (30 participants):

  • 30 cases treated with molnupiravir
  • Survival: 100%

2023 Study (18 cases):

  • 18 cats with FIP treated
  • Survival: 14 of 18 (77.8%)

University of California, Davis:

A clinical investigation began in July 2022 with the aim of establishing optimal dose and dosing interval, including pharmacokinetic data.

Current Use and Recommendations

⚠️ Regulatory Status and Clinical Use

In Spain: Its use is prohibited.

International Cat Care: Mentions it in current guidelines for:

  • Cases of therapeutic failure with GS-441524
  • Cats that have relapsed after treatment

Cyprus 2023: Health authorities granted exceptional authorisation for its use during the FIP epidemic that affected the island.

Dosing and Administration

💊 Dosing Protocol

Dose range: 10–20 mg/kg every 12 hours PO for 12 weeks, depending on clinical presentation

Recommendation: Do not exceed 15 mg/kg every 12 hours to minimise risk of adverse reactions

Monitoring: Monthly blood tests (same protocol as GS-441524)

Clinical Presentation Oral Dose
Effusion without ocular or neurological signs (abdominal or pleural) 10–15 mg/kg every 12h
No effusion without ocular or neurological signs 15 mg/kg every 12h
Ocular signs ± effusion 15 mg/kg every 12h
Neurological signs ± effusion 15–20 mg/kg every 12h

Adverse Reactions and Side Effects

⚠️ Adverse Effects of Molnupiravir

  • Bone marrow toxicity (>20 mg/kg): Neutropaenia
  • Hair loss: Loss of coat and whiskers
  • Ear fold: Folding of the ear tips
  • Gastrointestinal: Nausea, vomiting (administer with food to minimise)
  • Hepatopathy: Elevation of liver enzymes
  • Teratogenicity: Contraindicated in pregnancy
  • Arthropathy: Joint problems in young patients

Administering the drug with food may minimise gastrointestinal problems.

7. Mefloquine: A Cost-Effective Option

Mechanism of Action and History

💊 Antimalarial Drug with Antiviral Activity

Mefloquine is a human antimalarial drug, marketed under the brand name Lariam® (not available in Spain). It is used for cases of chloroquine-resistant Plasmodium falciparum.

Discovery for FIP: Through its investigation as a treatment for COVID-19, its potential efficacy against FIP has been postulated.

In vitro evidence: It has been shown to reduce the viral load of FIP in Crandell feline kidney cells without cytotoxic effect, inhibiting viral replication in vitro.

Scientific Evidence

📊 Studies with Chloroquine and Mefloquine

2013 Study (chloroquine):

Chloroquine, an antimalarial from the same family, was shown to have an inhibitory effect on FIP viral replication along with an anti-inflammatory effect in vitro. In experimentally infected cats, those treated with the drug showed better outcomes.

2020 Study (mefloquine):

An in vivo pharmacokinetic study of mefloquine that determined:

  • Efficacy of currently used doses
  • Description of haematological and biochemical changes
  • Safety profile in clinically normal cats

Dosing and Administration

💊 Dosing Protocol

Standard dose: 62.5 mg administered 2–3 times per week

Duration: Until completion of 84 days of treatment

Route: Oral

Combination Regimens

💊 Current Use of Mefloquine

There are therapeutic regimens in which mefloquine is used in different ways:

  • In combination with GS-441524: To potentiate antiviral effects
  • Cases with financial constraints: International Cat Care protocol as a more affordable alternative
  • Supportive therapy: In combination with other antivirals

Adverse Reactions and Side Effects

⚠️ Adverse Effects of Mefloquine

  • Vomiting: Most common gastrointestinal effect
  • Dermatopathies: Skin reactions
  • Elevation of SDMA: Marker of renal function

Recommendation: Administering the drug with food may minimise gastrointestinal problems.

8. New Antivirals Under Investigation

Nirmatrelvir: A Promising Future

🔬 Current Research

The journal Veterinary Sciences published an article in 2023 comparing the in vitro efficacy of various antivirals against FIP, yielding promising results with nirmatrelvir.

Nirmatrelvir: This human drug for COVID-19 is used in combination with ritonavir under the brand name Paxlovid® (Pfizer®).

Experimental veterinary use: According to personal communication from Dr Richard Malik, it has been used in cats refractory to other treatments.

Experimental Dosing

💊 Investigational Protocol

Reported dose: 75 mg nirmatrelvir + 25 mg ritonavir every 12 hours orally

This dosing is based on personal communication and individual cases treated by specialists. Formal clinical studies are required to establish definitive protocols.

Current State of Research

🔬 Active Lines of Investigation

The ongoing evolution in the study of the disease and its treatment generates new research:

  • Comparative in vitro studies: Evaluation of multiple antivirals
  • Clinical cases: Compassionate use in cats resistant to standard treatments
  • Pharmacokinetics: Studies needed to establish optimal doses
  • Combinations: Potential use with GS-441524 or remdesivir

⚠️ Warning on Experimental Use

Nirmatrelvir/ritonavir (Paxlovid®) is a medicine approved exclusively for human use. Its use in cats is limited to exceptional circumstances under the supervision of feline medicine specialists and when standard treatments have failed.

It is not approved for veterinary use and requires special prescription and close monitoring.

9. Current Treatment Protocols

Selecting the Appropriate Antiviral

🎯 Therapeutic Decision Algorithm

Clinical Situation First-Line Treatment
Effusive FIP without complications GS-441524 or Remdesivir
Non-effusive FIP GS-441524 or Remdesivir
Neurological FIP GS-441524 (high dose) or Remdesivir
Ocular FIP GS-441524 or Remdesivir
Resistance to GS-441524 GS-441524 + GC-376
Post-treatment relapse Restart GS-441524 (higher dose)
Financial constraints Mefloquine + GS (low dose)

Standard Treatment Duration

⏱️ Treatment Timelines

  • Standard protocol: 84 days (12 weeks)
  • Short investigational protocol: 42 days in selected cases
  • Extended protocol: >84 days in complex neurological cases or relapses
  • Combined protocol: 4–12 weeks depending on clinical response

Important: Treatment duration must be individualised according to each patient's clinical and analytical response.

Treatment Monitoring

🩺 Required Veterinary Check-Ups

Dr Pedersen established monitoring criteria in his original publication that remain standard practice:

  • Clinical assessment: Weekly for the first 2–4 weeks, then fortnightly
  • Full blood count: Every 2–4 weeks
  • Serum biochemistry: Every 2–4 weeks (total protein, albumin, globulins, bilirubin, ALT, creatinine)
  • Body weight: Weekly
  • Temperature: Daily at home during the first weeks
  • Effusion assessment: Ultrasound scan where applicable

Criteria for Therapeutic Success

✅ Indicators of Good Response

  • Clinical improvement: Increased activity and appetite within 3–7 days
  • Resolution of fever: Within the first 24–48 hours
  • Normalisation of proteins: Decrease in globulins, increase in albumin
  • Resolution of effusion: Within 2–4 weeks
  • Weight gain: Progressive throughout treatment
  • Normalisation of bilirubin: Particularly important for prognosis

Management of Relapses

🔄 Protocol for Relapses

Relapse rates have declined with optimised protocols (8–10% in recent studies), but when they do occur:

  • Immediate restart: Do not wait for clinical deterioration
  • Dose increase: Increase previous dose by 25–50% (typically an increase of 4 mg/kg)
  • Extended duration: A minimum of 84 additional days
  • Consider combinations: GS-441524 + GC-376

Complementary Supportive Therapies

💊 Adjunct Treatments

Although antivirals are the cornerstone of treatment, some supportive therapies may be beneficial:

  • Prednisolone (low dose): First 7–14 days for control of severe inflammation
  • Appetite stimulants: Mirtazapine, maropitant if severe anorexia
  • Fluid therapy: If dehydration or anorexia present
  • Nutritional support: Assisted feeding if necessary
  • Analgesia: If pain is evident
  • Anticoagulants: In cases at risk of thromboembolism

Note: Prolonged use of corticosteroids is not recommended, as it may interfere with the immune response required for recovery.

10. Frequently Asked Questions

How Much Does Antiviral FIP Treatment Cost?
The cost varies significantly depending on the country, the antiviral chosen, and the cat's weight. In general, a complete 84-day course of treatment with GS-441524 can range from approximately €400 to €4,000, depending on whether it is a legal or unlicensed formulation.
How Long Does It Take to See Improvement with Antiviral Treatment?
Improvement is usually rapid and dramatic. Fever should resolve within the first 24–48 hours. Appetite and activity improve noticeably within the first 3–7 days. If there is no improvement within the first week, the diagnosis or treatment protocol should be reassessed.
Can Cats Successfully Treated for FIP Relapse Afterwards?
Yes, although relapse rates have declined with optimised protocols (8–10%). Most relapses tend to occur within the first 10 days after completing treatment. If a relapse occurs, treatment can be restarted at higher doses and a good response is generally achieved.
Is It Legal to Buy GS-441524 Online Without a Veterinary Prescription?
The legal situation varies by country. In many European countries there is an "unlicensed" market for GS-441524 that owners purchase directly. However, it is always advisable to work with a vet who can supervise treatment. In some countries such as the United Kingdom, Australia and Italy, legal pathways already exist via compounding pharmacies.
What Should I Do If My Vet Is Not Familiar with These Treatments?
Although an increasing number of vets are familiar with antiviral FIP treatment, some practitioners may not be up to date. You can share published scientific studies (especially those by Dr Pedersen) and the International Cat Care guidelines. You can also seek a referral to a vet specialising in feline medicine or with experience in FIP treatment.
Can Cats Cured of FIP Pass It On to Other Cats?
FIP itself is never contagious; what is transmitted is the common coronavirus. Studies from 2022 show that treatment with GS-441524 effectively reduces viral load. Most cats stop shedding the virus during treatment. However, shedding may reactivate if the cat is re-exposed to feline coronavirus in multi-cat environments.
Is Any One Antiviral Better Than Another?
GS-441524 and remdesivir are considered the gold standard with the highest success rates (>90%). According to the University of Utah study, these antivirals have consistently demonstrated their effectiveness in the treatment of FIP.
Can FIP Be Treated in Very Young or Very Old Cats?
Yes. Antivirals have demonstrated efficacy in cats of all ages. Very young kittens (under 6 months) may require dose adjustments and closer monitoring due to possible dental effects with GC-376. Senior cats may have special considerations related to concurrent conditions, but age alone is not a contraindication.

11. Resources and Veterinary Support

Key Scientific Sources

📚 Essential Scientific Literature

  • Dr Niels Pedersen – UC Davis: All publications on GS-441524, GC-376 and treatment protocols
  • International Cat Care: Updated guidelines on FIP treatment
  • Journal of Feline Medicine and Surgery: Multiple studies on antivirals (2018–2025)
  • Veterinary Sciences: Comparative antiviral studies
  • WSAVA: List of essential medicines including antivirals for FIP

Specialist Veterinary Organisations

  • GEMFE (Feline Medicine Specialist Group – AVEPA) – Spain
  • International Society of Feline Medicine (ISFM) – International
  • American Association of Feline Practitioners (AAFP) – United States
  • European Advisory Board on Cat Diseases (ABCD) – Europe

When to Seek Specialist Veterinary Care

🩺 Situations Requiring a Specialist

  • Complex diagnosis: When symptoms are unclear
  • Neurological FIP: Requires specific protocols and specialist monitoring
  • Lack of response: If there is no improvement within the first week of treatment
  • Multiple relapses: Need to adjust protocols
  • Complications during treatment: Severe adverse effects
  • Access to legal antivirals: Vets with compounding pharmacy capability

Support Groups for Owners

💚 Community and Shared Experiences

There are numerous support groups on social media where owners share experiences of FIP treatment:

  • Pif Warriors España – Facebook group
  • @pifwarriors_es – Instagram
  • International forums with active veterinary professionals
  • WhatsApp and Telegram groups organised by country

Note: Whilst these groups can provide valuable emotional support, they should always operate under veterinary supervision. Self-medication without professional oversight can be dangerous.

Acknowledgements

🙏 Acknowledgements

The authors wish to thank Professor Sévérine Tasker for keeping us continually updated with the latest developments from International Cat Care, and the many GEMFE colleagues involved in the fight against this disease.

Conflicts of Interest

📋 Declaration of Independence

The authors have received no financial compensation in the writing of this article and declare no conflicts of interest with antiviral manufacturers, suppliers, or any commercial entity related to FIP treatment.

⚠️ Essential Veterinary Medical Disclaimer

This guide is informational and educational, based on published scientific literature. It does not replace professional veterinary consultation, diagnosis, or treatment.

IMPORTANT: FIP treatment with antivirals must always be carried out under veterinary supervision. Each case is unique and requires individualised protocols, regular analytical monitoring, and adjustments based on clinical response.

REMEMBER: FIP is no longer a death sentence. With the antivirals available today, more than 90% of cats can make a full recovery. Early diagnosis and treatment are essential for therapeutic success.